Senores Pharmaceuticals Limited

BSE:544319 Stock Report

Market Cap: ₹25.5b

Senores Pharmaceuticals Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Swapnil Shah

Chief executive officer

₹8.9m

Total compensation

CEO salary percentagen/a
CEO tenure3.3yrs
CEO ownership8.5%
Management average tenureless than a year
Board average tenure1.2yrs

Recent management updates

Recent updates


CEO

Swapnil Shah (39 yo)

3.3yrs

Tenure

₹8,910,000

Compensation

Mr. Swapnil Jatinbhai Shah is Managing Director of Senores Pharmaceuticals Limited and has been its Director since October 15, 2021. Mr. Shah is Chairman and Whole Time Director of Remus Pharmaceuticals Pr...


Leadership Team

NamePositionTenureCompensationOwnership
Swapnil Shah
MD & Directorno data₹8.91m8.52%
₹ 2.2b
Deval Shah
Whole-Time Director & CFOno data₹5.61mno data
Chetan Shah
Whole-Time Director & COOless than a year₹4.32mno data
Hanuwant Shaktawat
Assistant Vice President of HR & Adminless than a yearno datano data
Vinay Mishra
Company Secretary & Compliance Officerless than a yearno datano data
Deepak Jain
Vice President of Regulatory Affairsno datano datano data

0.7yrs

Average Tenure

58yo

Average Age

Experienced Management: 544319's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Swapnil Shah
MD & Director3.3yrs₹8.91m8.52%
₹ 2.2b
Deval Shah
Whole-Time Director & CFO5yrs₹5.61mno data
Chetan Shah
Whole-Time Director & COO1.2yrs₹4.32mno data
Sanjay Majmudar
Chairmanless than a yearno datano data
Manjula Devi Shroff
Non-Executive & Independent Directorless than a yearno datano data
Kalpit Gandhi
Non-Executive & Independent Directorless than a yearno datano data
Udayan Choksi
Non-Executive & Independent Directorless than a yearno datano data
Arpit Shah
Non-Executive & Non-Independent Director1.2yrsno datano data
Hemanshu Pandya
Non-Executive & Non-Independent Director1.2yrsno datano data
Jitendra Sanghvi
Non-Executive & Non-Independent Director3.2yrs₹200.00k1.77%
₹ 451.8m
Ashokkumar Barot
Non-Executive & Non-Independent Director6.7yrsno data10.35%
₹ 2.6b
Naresh Shah
Non-Executive & Independent Directorless than a yearno datano data

1.2yrs

Average Tenure

55.5yo

Average Age

Experienced Board: 544319's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/07 11:43
End of Day Share Price 2025/01/07 00:00
Earnings2024/03/31
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Senores Pharmaceuticals Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution